JP2019504067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504067A5 JP2019504067A5 JP2018535876A JP2018535876A JP2019504067A5 JP 2019504067 A5 JP2019504067 A5 JP 2019504067A5 JP 2018535876 A JP2018535876 A JP 2018535876A JP 2018535876 A JP2018535876 A JP 2018535876A JP 2019504067 A5 JP2019504067 A5 JP 2019504067A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- substituted
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 185
- 125000001424 substituent group Chemical group 0.000 claims 58
- 125000005843 halogen group Chemical group 0.000 claims 35
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 35
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000004432 carbon atoms Chemical group C* 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 125000005842 heteroatoms Chemical group 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- -1 3,6-dihydro-2H-pyran-4-yl Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152416.0 | 2016-01-22 | ||
| EP16152416 | 2016-01-22 | ||
| EP16159651.5 | 2016-03-10 | ||
| EP16159651 | 2016-03-10 | ||
| PCT/EP2017/051150 WO2017125530A1 (en) | 2016-01-22 | 2017-01-20 | New substituted cyanoindoline derivatives as nik inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504067A JP2019504067A (ja) | 2019-02-14 |
| JP2019504067A5 true JP2019504067A5 (pt) | 2020-03-05 |
| JP6910359B2 JP6910359B2 (ja) | 2021-07-28 |
Family
ID=57868252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535876A Active JP6910359B2 (ja) | 2016-01-22 | 2017-01-20 | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11180487B2 (pt) |
| EP (1) | EP3405196B1 (pt) |
| JP (1) | JP6910359B2 (pt) |
| KR (1) | KR20180100441A (pt) |
| CN (1) | CN108697710B (pt) |
| AU (1) | AU2017209935B2 (pt) |
| BR (1) | BR112018014675B1 (pt) |
| CA (1) | CA3011880A1 (pt) |
| DK (1) | DK3405196T3 (pt) |
| ES (1) | ES2775449T3 (pt) |
| HR (1) | HRP20200133T1 (pt) |
| HU (1) | HUE047684T2 (pt) |
| IL (1) | IL260500B (pt) |
| LT (1) | LT3405196T (pt) |
| MX (1) | MX2018008974A (pt) |
| PH (1) | PH12018501567A1 (pt) |
| SI (1) | SI3405196T1 (pt) |
| TW (1) | TWI739783B (pt) |
| WO (1) | WO2017125530A1 (pt) |
| ZA (1) | ZA201804688B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697710B (zh) | 2016-01-22 | 2022-02-18 | 杨森制药有限公司 | 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 |
| EP3405464B1 (en) | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| WO2018019204A1 (zh) | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| AU2018339722B2 (en) | 2017-09-30 | 2022-06-30 | Haihe Biopharma Co., Ltd | Compound having ERK kinase inhibitory activity and use thereof |
| TW202045008A (zh) | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| US20220177459A1 (en) * | 2019-04-02 | 2022-06-09 | Hinova Pharmaceuticals Inc. | Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators |
| UY38721A (es) | 2019-05-31 | 2020-11-30 | Janssen Pharmaceutica Nv | INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB |
| JPWO2023026794A1 (pt) | 2021-08-23 | 2023-03-02 | ||
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| HUP0301117A3 (en) | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
| US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
| DE60223790T4 (de) | 2001-03-29 | 2009-05-07 | Vertex Pharmaceuticals Inc., Cambridge | Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase |
| JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US20110086834A1 (en) | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| US9567318B2 (en) | 2009-08-17 | 2017-02-14 | Memorial Sloan-Kettering Cancer Center | Substituted pyrimidine compounds and uses thereof |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EA025611B1 (ru) | 2010-07-29 | 2017-01-30 | Райджел Фармасьютикалз, Инк. | Активирующие ampk гетероциклические соединения и способы их использования |
| CN103732067A (zh) | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | 化合物，组合物及它们的治疗用途 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| TWI692477B (zh) | 2013-08-30 | 2020-05-01 | 美商Ｐｔｃ治療公司 | 經取代嘧啶ｂｍｉ-１抑制劑 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| KR20170003553A (ko) | 2014-04-04 | 2017-01-09 | 사이로스 파마수티컬스, 인크. | 사이클린-의존성 키나제 7(cdk7)의 저해제 |
| CN106536478A (zh) | 2014-05-22 | 2017-03-22 | 悉尼大学 | ω‑3类似物 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| JP6499282B2 (ja) | 2014-09-26 | 2019-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| CN108697710B (zh) | 2016-01-22 | 2022-02-18 | 杨森制药有限公司 | 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 |
| EP3405464B1 (en) | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
-
2017
- 2017-01-20 CN CN201780007786.1A patent/CN108697710B/zh active Active
- 2017-01-20 KR KR1020187024257A patent/KR20180100441A/ko not_active Application Discontinuation
- 2017-01-20 TW TW105143703A patent/TWI739783B/zh not_active IP Right Cessation
- 2017-01-20 ES ES17701110T patent/ES2775449T3/es active Active
- 2017-01-20 MX MX2018008974A patent/MX2018008974A/es unknown
- 2017-01-20 BR BR112018014675-7A patent/BR112018014675B1/pt active IP Right Grant
- 2017-01-20 DK DK17701110.3T patent/DK3405196T3/da active
- 2017-01-20 WO PCT/EP2017/051150 patent/WO2017125530A1/en active Application Filing
- 2017-01-20 LT LTEP17701110.3T patent/LT3405196T/lt unknown
- 2017-01-20 HU HUE17701110A patent/HUE047684T2/hu unknown
- 2017-01-20 AU AU2017209935A patent/AU2017209935B2/en active Active
- 2017-01-20 EP EP17701110.3A patent/EP3405196B1/en active Active
- 2017-01-20 JP JP2018535876A patent/JP6910359B2/ja active Active
- 2017-01-20 CA CA3011880A patent/CA3011880A1/en active Pending
- 2017-01-20 US US16/071,192 patent/US11180487B2/en active Active
- 2017-01-20 SI SI201730183T patent/SI3405196T1/sl unknown
-
2018
- 2018-07-09 IL IL260500A patent/IL260500B/en active IP Right Grant
- 2018-07-13 ZA ZA2018/04688A patent/ZA201804688B/en unknown
- 2018-07-23 PH PH12018501567A patent/PH12018501567A1/en unknown
-
2020
- 2020-01-29 HR HRP20200133TT patent/HRP20200133T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504067A5 (pt) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| JP2016506958A5 (pt) | ||
| JP2019512505A5 (pt) | ||
| JP2019510798A5 (pt) | ||
| BRPI0407835A (pt) | composto, éster hidrolisável in vivo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal, solvato, pró-droga ou éster hidrolisável in vivo farmaceuticamente aceitável, composição farmacêutica, e, processo para a preparação de um composto ou seus sais, salvatos, pró-droga ou ésteres hidrolisáveis in vivo farmaceuticamente aceitáveis | |
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2016506369A5 (pt) | ||
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| JP2019529419A5 (pt) | ||
| JP2017512833A5 (pt) | ||
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| JP2016515560A5 (pt) | ||
| JP2016531858A5 (pt) | ||
| JP2016506960A5 (pt) | ||
| JP2014520898A5 (pt) | ||
| RU2011147232A (ru) | Производное карбоновой кислоты | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| JP2020531414A5 (pt) | ||
| JP2019524646A5 (pt) | ||
| JP2017501237A5 (pt) | ||
| JP2017503760A5 (pt) | ||
| JP2017512803A5 (pt) | ||
| TN2019000117A1 (en) | Liposomal formulation for use in the treatment of cancer | |
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |